Free Trial

Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy?

Autolus Therapeutics logo with Medical background

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $2.41, but opened at $2.57. Autolus Therapeutics shares last traded at $2.54, with a volume of 305,366 shares changing hands.

Analysts Set New Price Targets

AUTL has been the subject of several analyst reports. Truist Financial lowered their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Monday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $9.32.

Read Our Latest Report on AUTL

Autolus Therapeutics Price Performance

The company's fifty day moving average price is $2.04 and its 200 day moving average price is $1.89. The company has a market cap of $653.37 million, a PE ratio of -2.80 and a beta of 1.81.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $8.98 million for the quarter, compared to the consensus estimate of $1.59 million. On average, analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. EntryPoint Capital LLC bought a new position in Autolus Therapeutics during the fourth quarter worth about $450,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Autolus Therapeutics by 21.2% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 82,411 shares of the company's stock worth $194,000 after purchasing an additional 14,432 shares during the period. BIT Capital GmbH boosted its position in Autolus Therapeutics by 147.0% during the fourth quarter. BIT Capital GmbH now owns 636,979 shares of the company's stock worth $1,497,000 after purchasing an additional 379,050 shares during the period. Wellington Management Group LLP boosted its position in Autolus Therapeutics by 4.6% during the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock worth $59,562,000 after purchasing an additional 1,125,454 shares during the period. Finally, HighPoint Advisor Group LLC bought a new position in Autolus Therapeutics during the fourth quarter worth about $185,000. Institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Autolus Therapeutics Right Now?

Before you consider Autolus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.

While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines